



Review

Extrahepatic manifestations of hepatitis E virus: An overview

Fotios S. Fousekis, Ioannis V. Mitselos, and Dimitrios K. Christodoulou

Department of Gastroenterology and Hepatology, University Hospital of Ioannina, School of Health Sciences, University of Ioannina, Ioannina, Greece

Hepatitis E virus (HEV) is a significant health problem with approximately 20 million individuals infected annually. HEV infection has been associated with a wide spectrum of extrahepatic manifestations, including neurological, hematological and renal disorders. Guillain-Barré syndrome and neuralgic amyotrophy are the most frequent neurological manifestations. In addition, HEV infection has been observed with other neurological diseases, such as encephalitis, myelitis and Bell's palsy. Hematologic manifestations include anemia due to glucose-6-phosphate dehydrogenase deficiency, autoimmune hemolytic anemia and severe thrombocytopenia. Membranoproliferative glomerulonephritis and relapse IgA nephropathy with or without coexisting cryoglobulinemia appear to be the most common renal injuries related with HEV infection. Also, HEV infection has been associated with acute pancreatitis and other immune-mediated manifestations, such as arthritis and myocarditis. However, the pathophysiologic mechanisms of HEV-related extrahepatic manifestations are still largely unclear. **Clin Mol Hepatol 2019 Oct 11. [Epub ahead of print]**

Keywords: Hepatitis E; Kidney; Neurologic manifestations; Hematologic diseases

INTRODUCTION

Hepatitis E virus (HEV) is a single-stranded RNA virus and was first discovered in 1983,¹ but the viral genome was cloned in 1990.² It is estimated that HEV causes 20.1 million infections annually, leading to 3.4 million symptomatic cases with acute hepatitis and 70,000 deaths related to acute liver failure.³

HEV has eight genotypes. Genotypes 1 and 2 only infect humans, are detected mainly in Asia and Mexico, respectively and they spread through fecal-oral route. Genotypes 3 and 4 are detected mainly in Europe and North America, circulate in animal

species such as pigs, wild boars and deer and occasionally infect humans via consumption of contaminated meat or direct contact.⁴ Also, genotype 3 has been detected in shellfishes in Scotland and in southern Italy.^{5,6} Genotypes 5 and 6 have been only reported in wild boar and genotypes 7 and 8 have been identified in camels.⁷

The diagnostic tests for HEV infection include detection of antibodies against HEV (IgM anti-HEV and IgG anti-HEV) and detection of HEV RNA. IgM anti-HEV is positive during the first month after HEV infection, while IgG anti-HEV represents current or past infection.⁸ Detection of HEV RNA in blood or stool characterizes chronic or acute HEV infection. Chronic hepatitis E is defined as

Abbreviations:

AIHA, autoimmune hemolytic anemia; DAT, direct antiglobulin test; G-6-PD, glucose-6-phosphate dehydrogenase; GBS, Guillain-Barré syndrome; HAV, hepatitis A virus; HBV, hepatitis B virus; HEV, hepatitis E virus; MGUS, monoclonal gammopathy of undetermined significance; NA, neuralgic amyotrophy

Corresponding author : Dimitrios K. Christodoulou

Department of Gastroenterology and Hepatology, University of Ioannina, Stavrou Niarchou 1, Ioannina 45100, Greece
Tel: +302651099639, Fax: +302651007838
E-mail: dchristodoulou@gmail.com
<https://orcid.org/0000-0001-9694-1160>

Received : Sep. 3, 2019 / Accepted : Sep. 16, 2019

HEV RNA being detectable for at least 3 months. In immunosuppressed patients with chronic HEV infection, antibodies are often undetectable.⁹ HEV infection is usually self-limiting and causes acute mild illness. However, HEV infection during pregnancy, especially in the third trimester may lead to acute liver failure.¹⁰ Chronic HEV infection is rare and may develop in immunocompromised patients, such as organ transplant recipients.¹¹

In addition, HEV has been associated with a range of extrahepatic manifestations, including a spectrum of neurological symptoms and diseases, hematological disorders, renal diseases, acute pancreatitis, myocarditis, arthritis and autoimmune thyroiditis (Table 1).¹² However, the pathophysiologic mechanism of extrahepatic manifestations remains unclear. It seems that viral infections trigger a variety of host-defense mechanisms, which may not be

restricted to the primary location of infection and can cause cross-reactions between viral epitopes and self-antigens, leading to multisystemic manifestations. Another possible explanation is that HEV replicates not only in liver, but also in other tissues. HEV has been detected in neuronal cells,¹³ human placenta,¹⁴ breast milk,¹⁵ and urine.¹⁶

NEUROLOGICAL MANIFESTATIONS

Several neurological manifestations have been associated with HEV infection and include Guillain-Barré syndrome (acute inflammatory demyelinating polyradiculoneuropathy), neuralgic amyotrophy, encephalitis, myelitis, myositis, vestibular neuritis, peripheral neuropathy, Bell's palsy and mononeuritis multiplex.¹⁷ In a prospective multicenter study from United Kingdom, France and Netherlands it was found that 2.4% (11/464) of patients with non-traumatic neurologic injury had evidence of HEV infection.¹⁸ Also, a study from France demonstrated the neurologic disorders in patients infected with HEV and found that 16.5% of HEV-infected patients reported neurologic symptoms and neurological manifestations were more frequent in immunocompetent patients compared to immunosuppressed patients (22.6% vs. 3.2%, $P < 0.001$).¹⁹ However, a study from China compared the prevalence of acute hepatitis E between 1,117 patients diagnosed with neurological illness and 1,475 healthy controls and found that there was no difference (0.54% vs. 0.68%).²⁰ A possible explanation is the geographical distribution of HEV. The study from China was conducted in an area endemic for HEV genotype 4, while the European studies reported cases associated with HEV genotype 3. Therefore, HEV genotype 4 seems not to contribute to neurological disorders.²¹

Guillain-Barré syndrome

Guillain-Barré syndrome (GBS) is an acute onset immune-mediated disorder of peripheral nervous system and is characterized by acute inflammatory demyelinating polyradiculoneuropathy, causing rapidly progressing symmetric motor paralysis.²² HEV infection has been associated with development of GBS. Many studies have reported the high prevalence rate of HEV infection among GBS patients and several case reports have been documented showing the coexistence of acute hepatitis E with GBS. In Netherlands, 201 patients with GBS were compared with 201 healthy controls with a similar distribution in age, sex, and year of sampling and it

Table 1. Extrahepatic manifestations associated with hepatitis E virus infection

System	Manifestations
Neurological system	Guillain-Barré syndrome Neuralgic amyotrophy Encephalitis Myelitis Myositis Vestibular neuritis Peripheral neuropathy Bell's palsy Mononeuritis multiplex Seizure Pseudotumor cerebri Oculomotor palsy Polyradiculoneuropathy
Hematological system	Thrombocytopenia Monoclonal gammopathy of uncertain significance (MGUS) Hemolytic anemia Aplastic anemia Hemophagocytic syndrome CD30 (+) cutaneous T cell lymphoproliferative disorder Thrombotic thrombocytopenic purpura
Kidney	Relapse of IgA nephropathy Cryoglobulinemia Membranoproliferative glomerulonephritis
Heart	Myocarditis
Pancreas	Acute pancreatitis
Thyroid	Autoimmune thyroiditis Subacute thyroiditis
Skeletal system	Polyarthritis
Vasculitis	Henoch-Schönlein purpura

was found that the prevalence of acute hepatitis E was higher in patients with GBS compared with healthy controls (5% vs. 0.5%).²³ Additionally, in a similar study in Japan, 4.8% (3/63) of patients with GBS had acute HEV infection preceding the onset illness, while no patients from healthy control group (0/61) suffered from acute hepatitis E. Furthermore, a retrospective cohort study in Belgium found that the prevalence of HEV infection in patients with GBS was 8% (6/73).²⁴ In all studies, there were no differences regarding course and outcomes of GBS between HEV-related GBS and HEV-unrelated GBS. Also, cases of acute HEV infection have been found in pediatric patients with GBS.²⁵

Neuralgic amyotrophy

Neuralgic amyotrophy (NA), also known as Parsonage-Turner syndrome, is an acute and painful unique or multiple mononeuropathy in the upper extremity and is characterized by rapid multifocal motor weakness, amyotrophy and sensory loss.²⁶ It seems that HEV infection can trigger the development of NA and several studies have been conducted. A cohort study with 64 patients from United Kingdom and Netherlands found that 10% of patients with NA had acute hepatitis E, but HEV was not related to age, sex, severity, disease course or outcome.²⁷ Also, it seems that patients with NA and HEV have a distinct phenotype. A multicenter European study compared 61 HEV-NA patients with 61 NA patients and found that, HEV-NA appears more often predominantly bilateral asymmetrical involvement (80.0% vs. 8.6%, $P<0.001$) and more extensive damage to the brachial plexus. Involvement outside the brachial plexus is more common in HEV-NA (58.5% vs. 10.5%, $P<0.01$).²⁸

Other neurological manifestations

Other neurological cases associated with HEV infection include vestibular neuritis,²⁹ Bell's palsy,³⁰ acute ataxic neuropathy,³¹ transverse myelitis,³² acute encephalic Parkinsonism,³³ oculomotor palsy,³⁴ myositis,³⁵ seizure,³⁶ pseudotumor cerebri,³⁷ bilateral pyramidal syndrome,³⁸ polyradiculoneuropathy,³⁹ and mononeuritis multiplex.⁴⁰ In addition, central nervous system infections, such as encephalitis and meningitis, with HEV have been reported and HEV RNA has been demonstrated in serum and cerebrospinal fluid at the time of acute illness. Also, many patients with CNS infection were immunosuppressed as a result of solid organ transplantation.⁴¹

Pathogenic mechanism

The pathogenic mechanism between HEV and neurological disorders has been not clarified, but it seems that HEV is also neurotropic. Shedding of HEV RNA into the cerebrospinal fluid and intrathecal production of IgM anti-HEV has been detected in a patient with NA and acute HEV infection.⁴² Additionally, a study demonstrated that human neuronal-derived cell lines such as neuroepithelioma, desmoplastic cerebellar medulloblastoma, glioblastoma multiforme, glioblastoma astrocytoma and oligodendrocytic cells can support HEV RNA replication.⁴³

It is recommended that clinicians consider the possibility of HEV infection in patients with neurological disorders and concurrent liver enzyme alteration, especially those with peripheral nerve involvement.⁴⁴

RENAL MANIFESTATIONS

Renal disorders have been reported during HEV infection, including membranoproliferative glomerulonephritis and cryoglobulinemia. A retrospective study assessed kidney function and histology in 51 cases of solid-organ transplant patients during genotype 3 HEV infection and they observed statistically but not clinically significant decrease in estimated glomerular filtration rate (-5 mL/min, $P=0.04$) during HEV infection. In renal biopsies, glomerular diseases were identified. They included relapse of IgA nephropathy and membranoproliferative glomerulonephritis. The majority of these patients had cryoglobulinemia. After HEV clearance, cryoglobulinemia resolved and proteinuria and renal function improved.⁴⁵ Additional cases of HEV-related membranoproliferative glomerulonephritis and membranous nephropathy have been reported.^{46,47} In one case, HEV infection triggered monoclonal gammopathy of renal significance.⁴⁸

The association between cryoglobulinemia and HEV infection has not been fully investigated. In a study with solid organ recipients, who suffered from HEV infection, the prevalence of cryoglobulinemia was increased during chronic phase of infection (52.9%) compared to acute phase of infection (36.4%) and HEV-negative solid organ recipients (23.6%) ($P<0.01$). Also, HEV infection was identified as an independent predictive factor for cryoglobulinemia (odds ratio, 2.3).⁴⁹ Another retrospective study from Germany compared the prevalence of IgG anti-HEV between patients with cryoglobulinemia and healthy controls. They found that the anti-HEV seroprevalence rate was significantly higher in

patients with essential cryoglobulinemia than in non-essential cryoglobulinemia patients ($P=0.043$), suggesting that previous HEV contact might play a role in some cases of cryoglobulinemia that are currently classified as essential.⁵⁰

HEMATOLOGIC MANIFESTATIONS

Anemia

Different patterns of anemia have been reported during HEV infection, including hemolytic anemia due to glucose-6-phosphate dehydrogenase (G-6-PD) deficiency, autoimmune hemolytic anemia (AIHA) and aplastic anemia. Hemolytic anemia may be a complication of acute viral hepatitis and the frequency rate of hemolysis has been reported in up to 23% of patients. The prevalence of hemolytic anemia may rise up to 70% in patients who have G-6-PD deficiency.⁵¹ Patients with G-6-PD deficiency have low levels of glutathione in red blood cells, leading to accumulation of oxidants during viral hepatitis and resulting in hemolysis. Several cases of hemolysis in patients with G-6-PD deficiency and acute HEV infection have been reported.⁵²⁻⁵⁴ In some cases of hemolysis in patients with acute HEV infection and G-6-PD deficiency, there was development of renal failure, as a result of possible obstruction of renal tubules due to hemoglobin and bilirubin.^{55,56}

Autoimmune hemolytic anemia has been described in association with a variety of hepatotropic viruses, such as cytomegalovirus, hepatitis A virus (HAV) and hepatitis B virus (HBV).⁵⁷ AIHA is diagnosed based on clinical presentation, spherocytosis, laboratory findings and positive direct antiglobulin test (DAT). However, DAT was negative up to 15% of AIHA cases. In four published cases of AIHA-related with hepatitis E, the treatment was supportive and their outcomes were favorable.⁵⁸⁻⁶¹

Hepatitis-associated aplastic anemia is an uncommon but distinct variant of aplastic in which pancytopenia appears 2 or 3 months after an acute attack of viral hepatitis. Several viruses, such as parvovirus B19, cytomegalovirus, Epstein-Barr virus, HAV and HBV, have been associated with aplastic anemia.⁶² Three cases of HEV-related aplastic anemia have been reported. In one case there was no response to treatment with cyclosporine and in the second case, the patient expired due to sepsis and in the third case, the patient was treated with thymoglobulin, cyclosporine, corticosteroids, filgrastim and transfusions.⁶³⁻⁶⁵

Thrombocytopenia

Thrombocytopenia is a well-recognized complication of infections, including those from hepatotropic viruses. A variety of possible mechanisms of thrombocytopenia have been reported and includes hypersplenism, reduced hepatic production of thrombopoietin, bone marrow suppression by hepatotropic virus or treatment and development of anti-platelet autoantibodies and platelet-associated immune complexes.⁶⁶ Several cases of HEV-associated thrombocytopenia have been documented. In most cases, thrombocytopenia was self-limited, while in other cases, the patients needed to receive platelet transfusion, intravenous globulin and/ or corticosteroid. It is worth mentioning that, anti-platelet antibodies were detected in some cases of HEV-related thrombocytopenia.^{44,61,67,68}

Other hematological diseases

HEV infection has been related with other less common hematological disorders. Few cases of HEV-related hemophagocytic syndrome have been documented.⁶⁹⁻⁷¹ Also, HEV infection has been detected in patients with CD30 (+) cutaneous T cell lymphoproliferative disorder⁷² and monoclonal gammopathy of undetermined significance (MGUS). However, the relation between MGUS and HEV remains uncertain.⁷³ Additionally in one case, thrombotic thrombocytopenic purpura relapse induced by acute hepatitis E transmitted by cryosupernatant plasma. HEV infection treated with ribavirin and thrombotic thrombocytopenic purpura remitted with remission of HEV infection.⁷⁴

ACUTE PANCREATITIS

A wide variety of infectious agents has been associated with acute pancreatitis and these include viruses, bacteria and parasites. The association between acute pancreatitis and viral hepatitis is well known and HAV, HBV, and hepatitis C virus have been implicated most often.^{75,76} A proposed pathogenetic mechanism is the development of edema of the ambulla of Vater, causing obstruction of pancreatic fluid flow.⁷⁷ Several cases of HEV-induced acute pancreatitis have been reported.^{78,79} In a single-center study from France, 2.1% (16/790) of patients with acute pancreatitis had serological evidence of recent HEV infection with no other discernible cause of pancreatitis.⁸⁰ The typical profile of a patient is a young male from an endemic area or having recently travelled

to that area, who develops mild to moderate acute pancreatitis.⁸¹ However, life-threatening complications, such as, acute necrotizing pancreatitis, pseudocyst bleeding and multiorgan failure, have been reported.⁸²⁻⁸⁴

OTHER MANIFESTATIONS

Development of many other diseases has been reported during HEV infection, but further studies are needed to establish the association. In previous literatures, three cases of HEV-associated myocarditis have been reported.⁸⁵ Furthermore, HEV infection has been correlated with thyroid diseases. These include autoimmune thyroiditis, subacute thyroiditis and Grave's thyrotoxicosis.⁸⁶⁻⁸⁸ In addition, a case of Henoch-Schönlein purpura triggered by acute HEV infection⁸⁹ and another case of HEV-induced myasthenia Gravis have been described.⁹⁰ Lastly, HEV infection may cause acute polyarthritis.^{91,92}

CONCLUSION

Several extrahepatic manifestations and diseases have been documented during acute and chronic HEV infection. Neurologic diseases are demonstrated to be the most common extrahepatic manifestations of HEV infection, followed by hematological disorders and kidney injury. However, the pathophysiology of these manifestations and the causal relation with HEV infection remain ambiguous. Therefore, further studies are needed to estimate the epidemiological characteristics of HEV-related extrahepatic manifestations and to elucidate their underlying pathogenetic mechanisms.

Author's contribution

FSF: Data selection, writing, study design, IVM: writing, DKC: Supervision, study design, writing

Conflicts of Interest

The authors have no conflicts to disclose.

REFERENCES

- Balayan MS, Andjaparidze AG, Savinskaya SS, Ketiladze ES, Braginsky DM, Savinov AP, et al. Evidence for a virus in non-A, non-B hepatitis transmitted via the fecal-oral route. *Intervirology* 1983;20:23-31.
- Reyes GR, Purdy MA, Kim JP, Luk KC, Young LM, Fry KE, et al. Isolation of a cDNA from the virus responsible for enterically transmitted non-A, non-B hepatitis. *Science* 1990;247:1335-1339.
- Rein DB, Stevens GA, Theaker J, Wittenborn JS, Wiersma ST. The global burden of hepatitis E virus genotypes 1 and 2 in 2005. *Hepatology* 2012;55:988-997.
- Dalton HR, Hunter JG, Bendall RP. Hepatitis E. *Curr Opin Infect Dis* 2013;26:471-478.
- O'Hara Z, Crossan C, Craft J, Scobie L. First report of the presence of hepatitis E virus in Scottish-harvested shellfish purchased at retail level. *Food Environ Virol* 2018;10:217-221.
- La Rosa G, Proroga YTR, De Medici D, Capuano F, Iaconelli M, Della Libera S, et al. First detection of hepatitis E Virus in shellfish and in seawater from production areas in Southern Italy. *Food Environ Virol* 2018;10:127-131.
- Sridhar S, Teng JLL, Chiu TH, Lau SKP, Woo PCY. Hepatitis E virus genotypes and evolution: emergence of camel hepatitis E variants. *Int J Mol Sci* 2017;18:869.
- Aggarwal R. Diagnosis of hepatitis E. *Nat Rev Gastroenterol Hepatol* 2013;10:24-33.
- European Association for the Study of the Liver. EASL Clinical Practice Guidelines on hepatitis E virus infection. *J Hepatol* 2018;68:1256-1271.
- Kar P, Sengupta A. A guide to the management of hepatitis E infection during pregnancy. *Expert Rev Gastroenterol Hepatol* 2019;13:205-211.
- Kamar N, Selves J, Mansuy JM, Ouezani L, Péron JM, Guitard J, et al. Hepatitis E virus and chronic hepatitis in organ-transplant recipients. *N Engl J Med* 2008;358:811-817.
- Kamar N, Marion O, Abravanel F, Izopet J, Dalton HR. Extrahepatic manifestations of hepatitis E virus. *Liver Int* 2016;36:467-472.
- Pischke S, Hartl J, Pas SD, Lohse AW, Jacobs BC, Van der Eijk AA. Hepatitis E virus: infection beyond the liver? *J Hepatol* 2017;66:1082-1095.
- Bose PD, Das BC, Hazam RK, Kumar A, Medhi S, Kar P. Evidence of extrahepatic replication of hepatitis E virus in human placenta. *J Gen Virol* 2014;95(Pt 6):1266-1271.
- Rivero-Juarez A, Frias M, Rodriguez-Cano D, Cuenca-López F, Rivero A. Isolation of hepatitis E virus from breast milk during acute infection. *Clin Infect Dis* 2016;62:1464.
- Geng Y, Zhao C, Huang W, Harrison TJ, Zhang H, Geng K, et al. Detection and assessment of infectivity of hepatitis E virus in urine. *J Hepatol* 2016;64:37-43.
- McLean BN, Gulliver J, Dalton HR. Hepatitis E virus and neurological disorders. *Pract Neurol* 2017;17:282-288.
- Dalton HR, van Eijk JJJ, Cintas P, Madden RG, Jones C, Webb GW, et al. Hepatitis E virus infection and acute non-traumatic neurological

- injury: a prospective multicentre study. *J Hepatol* 2017;67:925-932.
19. Abravanel F, Pique J, Couturier E, Nicot F, Dimeglio C, Lhomme S, et al. Acute hepatitis E in French patients and neurological manifestations. *J Infect* 2018;77:220-226.
 20. Wang Y, Wang S, Wu J, Jiang Y, Zhang H, Li S, et al. Hepatitis E virus infection in acute non-traumatic neuropathy: a large prospective case-control study in China. *EBioMedicine* 2018;36:122-130.
 21. Horvatits T, Pischke S. Extrahepatic manifestations and HEV, the genotype matters. *EBioMedicine* 2018;36:3-4.
 22. Meena AK, Khadilkar SV, Murthy JM. Treatment guidelines for Guillain-Barré syndrome. *Ann Indian Acad Neurol* 2011;14(Suppl 1):S73-S81.
 23. van den Berg B, van der Eijk AA, Pas SD, Hunter JG, Madden RG, Tio-Gillen AP, et al. Guillain-Barré syndrome associated with preceding hepatitis E virus infection. *Neurology* 2014;82:491-497.
 24. Stevens O, Claeys KG, Poesen K, Saegeman V, Van Damme P. Diagnostic challenges and clinical characteristics of hepatitis E virus-associated Guillain-Barré syndrome. *JAMA Neurol* 2017;74:26-33.
 25. Geurtsvankessel CH, Islam Z, Mohammad QD, Jacobs BC, Endtz HP, Osterhaus AD. Hepatitis E and Guillain-Barre syndrome. *Clin Infect Dis* 2013;57:1369-1370.
 26. Seror P. Neuralgic amyotrophy. An update. *Joint Bone Spine* 2017;84:153-158.
 27. van Eijk JJ, Madden RG, van der Eijk AA, Hunter JG, Reimerink JH, Bendall RP, et al. Neuralgic amyotrophy and hepatitis E virus infection. *Neurology* 2014;82:498-503.
 28. van Eijk JJ, Dalton HR, Ripellino P, Madden RG, Jones C, Fritz M, et al. Clinical phenotype and outcome of hepatitis E virus-associated neuralgic amyotrophy. *Neurology* 2017;89:909-917.
 29. Woolson KL, Forbes A, Vine L, Beynon L, McElhinney L, Panayi V, et al. Extra-hepatic manifestations of autochthonous hepatitis E infection. *Aliment Pharmacol Ther* 2014;40:1282-1291.
 30. Jha AK, Nijhawan S, Nepalia S, Suchismita A. Association of Bell's Palsy with hepatitis E virus infection: a rare entity. *J Clin Exp Hepatol* 2012;2:88-90.
 31. Bruffaerts R, Yuki N, Damme PV, Moortele MV, Wautier M, Lagrou K, et al. Acute ataxic neuropathy associated with hepatitis E virus infection. *Muscle Nerve* 2015;52:464-465.
 32. Sarkar P, Morgan C, Ijaz S. Transverse myelitis caused by hepatitis E: previously undescribed in adults. *BMJ Case Rep* 2015;2015:bcr2014209031.
 33. Pasha SA, Pasha SA, Suhasini T, Rao DA. Hepatitis E virus-associated acute encephalitic parkinsonism. *J Assoc Physicians India* 2018;66:92-93.
 34. Yadav KK, Rohatgi A, Sharma SK, Kulshrestha M, Sachdeva S, Pardasani V. Oculomotor palsy associated with hepatitis E infection. *J Assoc Physicians India* 2002;50:737.
 35. Mengel AM, Stenzel W, Meisel A, Buning C. Hepatitis E-induced severe myositis. *Muscle Nerve* 2016;53:317-320.
 36. Kejariwal D, Roy S, Sarkar N. Seizure associated with acute hepatitis E. *Neurology* 2001;57:1935.
 37. Thapa R, Mallick D, Biswas B. Pseudotumor cerebri in childhood hepatitis E virus infection. *Headache* 2009;49:610-611.
 38. Kamar N, Izopet J, Cintas P, Garrouste C, Uro-Coste E, Cointault O, et al. Hepatitis E virus-induced neurological symptoms in a kidney-transplant patient with chronic hepatitis. *Am J Transplant* 2010;10:1321-1324.
 39. Despierres LA, Kaphan E, Attarian S, Cohen-Bacrie S, Pelletier J, Pouget J, et al. Neurologic disorders and hepatitis E, France, 2010. *Emerg Infect Dis* 2011;17:1510-1512.
 40. Perrin HB, Cintas P, Abravanel F, Gérolami R, d'Alterroche L, Raynal JN, et al. Neurologic disorders in immunocompetent patients with autochthonous acute hepatitis E. *Emerg Infect Dis* 2015;21:1928-1934.
 41. Dalton HR, Kamar N, van Eijk JJ, McLean BN, Cintas P, Bendall RP, et al. Hepatitis E virus and neurological injury. *Nat Rev Neurol* 2016;12:77-85.
 42. Fritz M, Berger B, Schemmerer M, Endres D, Wenzel JJ, Stich O, et al. Pathological cerebrospinal fluid findings in patients with neuralgic amyotrophy and acute hepatitis E virus infection. *J Infect Dis* 2018;217:1897-1901.
 43. Drave SA, Debing Y, Walter S, Todt D, Engelmann M, Friesland M, et al. Extra-hepatic replication and infection of hepatitis E virus in neuronal-derived cells. *J Viral Hepat* 2016;23:512-521.
 44. Bazerbachi F, Haffar S, Garg SK, Lake JR. Extra-hepatic manifestations associated with hepatitis E virus infection: a comprehensive review of the literature. *Gastroenterol Rep (Oxf)* 2016;4:1-15.
 45. Kamar N, Weclawiak H, Guilbeau-Frugier C, Legrand-Abravanel F, Cointault O, Ribes D, et al. Hepatitis E virus and the kidney in solid-organ transplant patients. *Transplantation* 2012;93:617-623.
 46. Del Bello A, Guilbeau-Frugier C, Josse AG, Rostaing L, Izopet J, Kamar N. Successful treatment of hepatitis E virus-associated cryoglobulinemic membranoproliferative glomerulonephritis with ribavirin. *Transpl Infect Dis* 2015;17:279-283.
 47. Taton B, Moreau K, Lepreux S, Bachelet T, Trimoulet P, De Ledinghen V, et al. Hepatitis E virus infection as a new probable cause of de novo membranous nephropathy after kidney transplantation. *Transpl Infect Dis* 2013;15:E211-E215.
 48. Agrawal P, Kumar V, Kumar A, Sachdeva MUS, Malhotra P, Nada R. Monoclonal gammopathy of renal significance triggered by viral E hepatitis. *Indian J Nephrol* 2019;29:50-52.
 49. Marion O, Abravanel F, Del Bello A, Esposito L, Lhomme S, Puissant-Lubrano B, et al. Hepatitis E virus-associated cryoglobulinemia in solid-organ-transplant recipients. *Liver Int* 2018;38:2178-2189.
 50. Pischke S, Polywka S, Haag F, Iking-Konert C, Sterneck M, Lütgehetmann M, et al. Association of hepatitis E virus and essential cryo-

- globulinemia? *J Clin Virol* 2015;67:23-24.
51. Chau TN, Lai ST, Lai JY, Yuen H. Haemolysis complicating acute viral hepatitis in patients with normal or deficient glucose-6-phosphate dehydrogenase activity. *Scand J Infect Dis* 1997;29:551-553.
52. Monga A, Makkar RP, Arora A, Mukhopadhyay S, Gupta AK. Case report: acute hepatitis E infection with coexistent glucose-6-phosphate dehydrogenase deficiency. *Can J Infect Dis* 2003;14:230-231.
53. Au WY, Ngai CW, Chan WM, Leung RY, Chan SC. Hemolysis and methemoglobinemia due to hepatitis E virus infection in patient with G6PD deficiency. *Ann Hematol* 2011;90:1237-1238.
54. Jain AK, Sircar S, Jain M, Adkar S, Waghmare C, Chahwala F. Increased morbidity in acute viral hepatitis with glucose-6-phosphate dehydrogenase deficiency. *Indian J Gastroenterol* 2013;32:133-134.
55. Ahmad BS, Ahmad A, Jamil S, Abubakar Mohsin Ehsanullah SA, Munir A. Severe haemolysis and renal failure precipitated by hepatitis E virus in G6PD Deficient patient: a case report. *J Pak Med Assoc* 2018;68:1397-1399.
56. Abid S, Khan AH. Severe hemolysis and renal failure in glucose-6-phosphate dehydrogenase deficient patients with hepatitis E. *Am J Gastroenterol* 2002;97:1544-1547.
57. Tibble JA, Ireland A, Duncan JR. Acute auto immune haemolytic anaemia secondary to hepatitis A infection. *Clin Lab Haematol* 1997;19:73-75.
58. Jin SQ, Chen XR, Wu XL, Han QX. A report of acute hepatitis E with immunologic hemolysis. *Zhonghua Gan Zang Bing Za Zhi* 2005;13:120.
59. Leaf RK, O'Brien KL, Leaf DE, Drews RE. Autoimmune hemolytic anemia in a young man with acute hepatitis E infection. *Am J Hematol* 2017;92:E77-E79.
60. Mishra P, Mahapatra M, Kumar R, Pati HP. Autoimmune hemolytic anemia and erythroid hypoplasia associated with hepatitis E. *Indian J Gastroenterol* 2007;26:195-196.
61. Thapa R, Ghosh A. Childhood autoimmune hemolytic anemia following hepatitis E virus infection. *J Paediatr Child Health* 2009;45:71-72.
62. Rauff B, Idrees M, Shah SA, Butt S, Butt AM, Ali L, et al. Hepatitis associated aplastic anemia: a review. *Virol J* 2011;8:87.
63. Zylberman M, Turdó K, Odzak A, Arcondo F, Altabert N, Munné S. Hepatitis E virus-associated aplastic anemia. Report of a case. *Medicina (B Aires)* 2015;75:175-177.
64. Shah SA, Lal A, Idrees M, Hussain A, Jeet C, Malik FA, et al. Hepatitis E virus-associated aplastic anaemia: the first case of its kind. *J Clin Virol* 2012;54:96-97.
65. Amarapurkar DN, Amarapurkar AD. Extrahepatic manifestations of viral hepatitis. *Ann Hepatol* 2002;1:192-195.
66. Stasi R, Chia LW, Kalkur P, Lowe R, Shannon MS. Pathobiology and treatment of hepatitis virus-related thrombocytopenia. *Mediterr J Hematol Infect Dis* 2009;1:e2009023.
67. Masood I, Rafiq A, Majid Z. Hepatitis E presenting with thrombocytopenia. *Trop Doct* 2014;44:219-220.
68. Singh NK, Gangappa M. Acute immune thrombocytopenia associated with hepatitis E in an adult. *Am J Hematol* 2007;82:942-943.
69. Kaur S, Kulkarni KP, Mahajan A, Sibal A. Hemophagocytosis associated with hepatitis a and e coinfection in a young child. *Indian J Hematol Blood Transfus* 2011;27:117-118.
70. Leroy M, Coiffier G, Pronier C, Triquet L, Perdriger A, Guggenbuhl P. Macrophage activation syndrome with acute hepatitis E during tocilizumab treatment for rheumatoid arthritis. *Joint Bone Spine* 2015;82:278-279.
71. Kamihira T, Yano K, Tamada Y, Matsumoto T, Miyazato M, Nagaoka S, et al. Case of domestically infected hepatitis E with marked thrombocytopenia. *Nihon Shokakibyo Gakkai Zasshi* 2008;105:841-846.
72. Mallet V, Bruneau J, Zuber J, Alanio C, Leclerc-Mercier S, Roque-Afonso AM, et al. Hepatitis E virus-induced primary cutaneous CD30(+) T cell lymphoproliferative disorder. *J Hepatol* 2017;67:1334-1339.
73. Forbes A, Woolson KL, Dalton HR. Letter: Monoclonal gammopathy of HEV infection. When is it significant? - authors' reply. *Aliment Pharmacol Ther* 2015;41:1028.
74. Riveiro-Barciela M, Bes M, Quer J, Valcarcel D, Piriz S, Gregori J, et al. Thrombotic thrombocytopenic purpura relapse induced by acute hepatitis E transmitted by cryosupernatant plasma and successfully controlled with ribavirin. *Transfusion* 2018;58:2501-2505.
75. Haffar S, Bazerbachi F, Prokop L, Watt KD, Murad MH, Chari ST. Frequency and prognosis of acute pancreatitis associated with fulminant or non-fulminant acute hepatitis A: a systematic review. *Pancreatol* 2017;17:166-175.
76. Parenti DM, Steinberg W, Kang P. Infectious causes of acute pancreatitis. *Pancreas* 1996;13:356-371.
77. Tsui CY, Burch GE, Harb JM. Pancreatitis in mice infected with coxsackievirus B1. *Arch Pathol* 1972;93:379-389.
78. Makharia GK, Garg PK, Tandon RK. Acute pancreatitis associated with acute hepatitis E infection. *Trop Gastroenterol* 2003;24:200-201.
79. Jaroszewicz J, Flisiak R, Kalinowska A, Wierzbicka I, Prokopowicz D. Acute hepatitis E complicated by acute pancreatitis: a case report and literature review. *Pancreas* 2005;30:382-384.
80. Raj M, Kumar K, Ghoshal UC, Saraswat VA, Aggarwal R, Mohindra S. Acute hepatitis E-associated acute pancreatitis: a single center experience and literature review. *Pancreas* 2015;44:1320-1322.
81. Haffar S, Bazerbachi F, Garg S, Lake JR, Freeman ML. Frequency and prognosis of acute pancreatitis associated with acute hepatitis E: a systematic review. *Pancreatol* 2015;15:321-326.
82. Deniel C, Coton T, Brardjanian S, Guisset M, Nicand E, Simon F. Acute pancreatitis: a rare complication of acute hepatitis E. *J Clin*

- Virol 2011;51:202-204.
83. Karanth SS, Khan Z, Rau NR, Rao K. Acute hepatitis E complicated by acute pancreatitis and multiorgan dysfunction. *BMJ Case Rep* 2014;2014:bcr2014203875.
 84. Somani SK, Ghosh A, Awasthi G. Severe acute pancreatitis with pseudocyst bleeding due to hepatitis E virus infection. *Clin J Gastroenterol* 2009;2:39-42.
 85. Premkumar M, Rangegowda D, Vashishtha C, Bhatia V, Khumuckham JS, Kumar B. Acute viral hepatitis E is associated with the development of myocarditis. *Case Reports Hepatol* 2015;2015:458056.
 86. Dumoulin FL, Liese H. Acute hepatitis E virus infection and autoimmune thyroiditis: yet another trigger? *BMJ Case Rep* 2012;2012:bcr1220115441.
 87. Martinez-Artola Y, Poncino D, García ML, Munné MS, González J, García DS. Acute hepatitis E virus infection and association with a subacute thyroiditis. *Ann Hepatol* 2015;14:141-142.
 88. Hui AY, Chan HL, Chan FK, Leung NW, Sung JJ. Fulminant hepatic failure in a patient with inactive HBsAg carrier state, acute hepatitis E and thyrotoxicosis. *Hepatol Res* 2003;27:248-251.
 89. Thapa R, Biswas B, Mallick D. Henoch-Schönlein purpura triggered by acute hepatitis E virus infection. *J Emerg Med* 2010;39:218-219.
 90. Belbezier A, Deroux A, Sarrot-Reynauld F, Larrat S, Bouillet L. Myasthenia gravis associated with acute hepatitis E infection in immunocompetent woman. *Emerg Infect Dis* 2014;20:908-910.
 91. Bialé L, Lecoules S, Galéano-Cassaz C, Carmoi T, Algayres JP. Inflammatory polyarthralgia revealing acute hepatitis E. *Presse Med* 2013;42:365-367.
 92. Serratrice J, Disdier P, Colson P, Ene N, de Roux CS, Weiller PJ. Acute polyarthrititis revealing hepatitis E. *Clin Rheumatol* 2007;26:1973-1975.